People · Operator
Named in public records as an officer, director or promoter · active 2009–2021 · Pharmaceuticals, Other Health Care, Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Cortexyme, Inc. | — | Pharmaceuticals | Series C | $111.5M | $71.9M | 2015 |
| Alvine Pharmaceuticals Inc | — | Other Health Care | Series B | $47.0M | $133.1M | 2009 |
| Bioniz Therapeutics, Inc. | — | Biotechnology | Series B | $23.6M | $317.5M | 2015 |
| Satori Pharmaceuticals Inc | — | Pharmaceuticals | Series A | $22.3M | $464.6M | 2010 |
| Via Nova Therapeutics, Inc. | — | Biotechnology | Series A | $5.0M | $102.9M | 2021 |
| Chimeros Inc | — | Other Health Care | Pre-Seed | $4.1M | $11.6M | 2009 |
Ilan Zipkin at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Ilan Zipkin on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Michael Powell | 1 | 14 |
| Edward Mathers | 1 | 12 |
| Frank Foster | 1 | 12 |
| Nina Kjellson | 1 | 11 |
| David Schnell | 1 | 7 |
| Chris Ehrlich | 1 | 6 |
| Una Ryan | 1 | 4 |
| John Mendlein | 1 | 4 |
| Casey Lynch | 1 | 4 |
| Stephen Watkins | 1 | 4 |
| Daphne Zohar | 1 | 4 |
| Kleanthis Xanthopoulos | 1 | 4 |
| Dirk Thye | 1 | 3 |
| Joe Kiani | 1 | 3 |
| Steven Holtzman | 1 | 3 |
| Joseph Jimenez | 1 | 3 |
| Miguel De Los Rios | 1 | 3 |
| L. Patrick Gage | 1 | 3 |
| William Ringo | 1 | 3 |
| Charles Ryan | 1 | 3 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.